Oxaliplatin is a platinum agent that is used for treatment of colorectal cancer. A sensitive and 2 selective hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the 3 quantification of oxaliplatin was developed. Human plasma ultrafiltrates were precipitated by 4 acetonitrile containing carboplatin as an internal standard and further diluted with acetonitrile.
Materials and methods
Oxaliplatin, carboplatin, and acetic acid were purchased from Wako (Osaka, Japan). Purity of plasma with sodium heparin as the anticoagulant was obtained from Terumo (Tokyo, Japan). A stock solution of oxaliplatin was prepared in methanol/water (50:50, v/v) at a concentration of 100 5 μg/mL and was stored at -80°C. As an internal standard solution, 10 μg/mL carboplatin in 6 acetonitrile was stored in the dark at -80°C. 9 We obtained human plasma ultrafiltrates using Centrifree ® Uitrafiltration Devices purchased from 10 Millipore (Tokyo, Japan). Calibration standards of oxaliplatin in human plasma ultrafiltrates were 11 prepared by diluting a stock solution at a concentration of 5000 ng/mL and serially diluting a plasma 
Preparation of calibration standards and validation samples

Sample preparation 18
Human plasma ultrafiltrates were precipitated by acetonitrile containing carboplatin as the internal 19 standard. To 40-μL sample volumes, 60 μL internal standard in acetonitrile containing 10000 ng/mL 20 of internal standard was added. The samples were then centrifuged for 10 min at 10,000×g. The The HPLC system consisted of a fully equipped Prominence20A (Shimadzu, Kyoto, Japan).
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For the analytical column, we used PC HILIC (50 × 2.0 mm i.d., 3 μm, Shiseido, Tokyo, Japan). The Mass spectrometry was carried out in an API3200 triple quadrupole mass spectrometer 10 (Applied Biosystems, Foster City, CA). Positive ionization electrospray mass spectrometry was 11 performed. For the determination oxaliplatin, the ionspray voltage was set at 5000 V. The turbospray 12 gas (N 2 ) probe was heated at 500°C. Nitrogen was used as curtain gas, gas 1 and gas 2, and their 13 flows were set to 50, 60 and 80 units, respectively. Unit mass resolution was set in both mass 14 resolving quadrupole Q1 and Q3. The declustering potential (DP) and collision energy (CE) for 15 oxaliplatin were 32 V and 19 eV, and these for internal standard were 46 V and 27 eV, respectively. The matrix effect of components from human plasma ultrafiltrates on oxaliplatin ionization 2 was also evaluated at three concentrations by comparing peak areas obtained from plasma 3 ultrafiltrate samples after extraction with those obtained from samples without matrix components.
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For infusion experiments, reference standard oxaliplatin (50 μg/mL, 0.1 mL/min) was 5 continually infused and then the corresponding matrix samples with (processed samples) or without 6 dilution (only protein precipitation samples) with acetonitrile were injected. 7 8 2.6. Application to clinical pharmacokinetic study 9 The method was applied to the determination of plasma concentrations of oxaliplatin in a colorectal 10 cancer patient hospitalized in Hokkaido University Hospital. Before treatment, the patient gave 11 written informed consent as approved by the institutional review board. We applied our method to 1 25, 50, 500 and 5000 ng/mL, for oxaliplatin. The results are summarized in Table 1 . For the 2 determination of oxaliplatin, the intra-and inter-day precisions were less than 6.1% for all 3 concentrations. The accuracies were within ±4.5% for all concentrations. These results suggest that 4 intact oxaliplatin in human plasma can be measured accurately and reproducibly by the present 5 method. Fig. 2A, 2B . There is no interference from an endogenous substance. The stability of oxaliplatin in human plasma ultrafiltrates is shown in Table 2 . We confirmed that 14 oxaliplatin in human plasma ultrafiltrates is stable for 4 weeks at a temperature below -80°C, 4 15 hours at a temperature below 4°C, and after processing. In addition, freeze-thaw stability also had 16 good value. Therefore, we decided to preserve oxaliplatin in human plasma ultrafiltrates at -80°C 17 and thaw them just before measurement. 
Extraction recovery from human plasma ultrafiltrates and matrix effect 20
The extraction recoveries from human plasma ultrafiltrates were 83.6-91.6% (Table 3) . Ion 21 suppression caused by the matrix components is shown in Fig. 3 . Because of the matrix components, 22 ionization of oxaliplatin was suppressed to 50% ( Fig. 3 (B) ); however, by diluting plasma with 23 acetonitrile, ionization of oxaliplatin recovered to nearly 90% (Fig. 3 (C) ). The dilution of matrix 24 components with acetonitrile was possible to remove the effect of matrix components and improve 
